KR860001147B1 - 지속성 니카르디핀 제제용 조성물의 제조방법 - Google Patents
지속성 니카르디핀 제제용 조성물의 제조방법 Download PDFInfo
- Publication number
- KR860001147B1 KR860001147B1 KR8205782A KR820005782A KR860001147B1 KR 860001147 B1 KR860001147 B1 KR 860001147B1 KR 8205782 A KR8205782 A KR 8205782A KR 820005782 A KR820005782 A KR 820005782A KR 860001147 B1 KR860001147 B1 KR 860001147B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- organic solvent
- nicardipine
- mixture
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims description 104
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 title claims description 26
- 229960001783 nicardipine Drugs 0.000 title claims description 26
- 238000000034 method Methods 0.000 title claims description 9
- 239000003814 drug Substances 0.000 claims description 18
- 239000003960 organic solvent Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 239000000654 additive Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 230000000996 additive effect Effects 0.000 claims description 12
- 230000001419 dependent effect Effects 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229920003169 water-soluble polymer Polymers 0.000 claims description 10
- 238000005507 spraying Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000003791 organic solvent mixture Substances 0.000 claims description 5
- 230000000149 penetrating effect Effects 0.000 claims description 5
- 239000004531 microgranule Substances 0.000 claims description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052759 nickel Inorganic materials 0.000 claims 2
- 230000005923 long-lasting effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 20
- 238000000576 coating method Methods 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 7
- 230000002688 persistence Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 229920003139 Eudragit® L 100 Polymers 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 5
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000011343 solid material Substances 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- -1 N-benzyl-N-methylamino Chemical group 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- HHAVHBDPWSUKHZ-UHFFFAOYSA-N propan-2-ol;propan-2-one Chemical compound CC(C)O.CC(C)=O HHAVHBDPWSUKHZ-UHFFFAOYSA-N 0.000 description 2
- TZDPJNSHSWMCPN-UHFFFAOYSA-N 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid Chemical compound OC(=O)C1=C(C)NC(C)=C(C(O)=O)C1C1=CC=CC([N+]([O-])=O)=C1 TZDPJNSHSWMCPN-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- CSVGEMRSDNSWRF-UHFFFAOYSA-L disodium;dihydrogen phosphate Chemical compound [Na+].[Na+].OP(O)([O-])=O.OP(O)([O-])=O CSVGEMRSDNSWRF-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP208608 | 1981-12-23 | ||
| JP268608 | 1981-12-23 | ||
| JP56208608A JPS58116414A (ja) | 1981-12-23 | 1981-12-23 | ニカルジピン持続性製剤用球形顆粒およびその製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR840002652A KR840002652A (ko) | 1984-07-16 |
| KR860001147B1 true KR860001147B1 (ko) | 1986-08-18 |
Family
ID=16559022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR8205782A Expired KR860001147B1 (ko) | 1981-12-23 | 1982-12-23 | 지속성 니카르디핀 제제용 조성물의 제조방법 |
Country Status (8)
| Country | Link |
|---|---|
| KR (1) | KR860001147B1 (enExample) |
| AT (1) | AT386743B (enExample) |
| CA (1) | CA1200494A (enExample) |
| ES (1) | ES518487A0 (enExample) |
| GR (1) | GR77096B (enExample) |
| IT (1) | IT1200966B (enExample) |
| MX (1) | MX7567E (enExample) |
| PT (1) | PT76023B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8414220D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2117571C3 (de) * | 1971-04-10 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
| EP0001247A1 (en) * | 1977-09-14 | 1979-04-04 | Kanebo, Ltd. | Pharmaceutical preparation containing nifedipine and a method for producing the same. |
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
-
1982
- 1982-12-16 MX MX82101116U patent/MX7567E/es unknown
- 1982-12-20 AT AT0460682A patent/AT386743B/de not_active IP Right Cessation
- 1982-12-21 GR GR70132A patent/GR77096B/el unknown
- 1982-12-21 CA CA000418228A patent/CA1200494A/en not_active Expired
- 1982-12-22 ES ES518487A patent/ES518487A0/es active Granted
- 1982-12-22 IT IT68503/82A patent/IT1200966B/it active Protection Beyond IP Right Term
- 1982-12-22 PT PT76023A patent/PT76023B/pt unknown
- 1982-12-23 KR KR8205782A patent/KR860001147B1/ko not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| KR840002652A (ko) | 1984-07-16 |
| MX7567E (es) | 1989-10-27 |
| ES8402156A1 (es) | 1984-02-01 |
| AT386743B (de) | 1988-10-10 |
| PT76023A (en) | 1983-01-01 |
| GR77096B (enExample) | 1984-09-06 |
| PT76023B (en) | 1986-02-12 |
| IT1200966B (it) | 1989-01-27 |
| ATA460682A (de) | 1988-03-15 |
| CA1200494A (en) | 1986-02-11 |
| IT8268503A0 (it) | 1982-12-22 |
| ES518487A0 (es) | 1984-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6780435B2 (en) | Omeprazole formulation | |
| US5028664A (en) | Drug-release controlling coating material for long acting formulations | |
| EP0164959B1 (en) | Pharmaceutical composition in sustained release unit dose form and process for its preparation | |
| KR910002641B1 (ko) | 산불안정화합물의 내복용 제제 | |
| US7022342B2 (en) | Controlled release oral dosage form of beta-adrenergic blocking agents | |
| US4758437A (en) | Composition for long acting nicardipine preparation and process of producing the composition | |
| CS268819B2 (en) | Method of particles production with effective substance's controlled loosening | |
| DE3024858A1 (de) | Anhaltend freigebende pharmazeutische zubereitung eines festen medikamentmaterials | |
| CZ279809B6 (cs) | Farmaceutický přípravek skládající se z granulí obsahujících tetracyklinovou sloučeninu | |
| DE60006362T2 (de) | Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen | |
| JPS58116414A (ja) | ニカルジピン持続性製剤用球形顆粒およびその製造法 | |
| KR100209201B1 (ko) | 1,4-디히드로피리딘 유도체를 함유하는 고체 분산 정제 및 그의 제조방법 | |
| JP2000053563A (ja) | 苦味がマスクされた速放性細粒剤 | |
| KR860001147B1 (ko) | 지속성 니카르디핀 제제용 조성물의 제조방법 | |
| PL180979B1 (pl) | Sposób wytwarzania karbamazepinowej postaci lekarstwa z opóźnionym uwalnianiem substancji biologicznie czynnej | |
| US5258186A (en) | Drug release controlling coating material for long acting formulations | |
| ES2860694T3 (es) | Composición farmacéutica de liberación sostenida que contiene rivastigmina | |
| WO2005023236A1 (en) | Phenylephrine tannate, pyrilamine tannate, and dextromethorphan tannate salts in pharmaceutical compositions | |
| US20020086057A1 (en) | Stabilized fromulations comprising hydrolytically unstable compositions | |
| JPH0236571B2 (ja) | Jizokuseiseizai | |
| KR100479637B1 (ko) | 란소프라졸을 함유하는 경구제제 및 그의 제조방법 | |
| JPH06305960A (ja) | チオウレア誘導体含有固形製剤 | |
| JPS615010A (ja) | 水素添加麦角アルカロイド徐放性製剤及びその製法 | |
| KR100552420B1 (ko) | 난용성 약물의 서방형 정제 | |
| JPH0710756A (ja) | 塩酸ニカルジピン徐放製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19821223 |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19840727 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19821223 Comment text: Patent Application |
|
| PG1605 | Publication of application before grant of patent |
Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19860722 |
|
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19861106 |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19861125 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19861125 End annual number: 3 Start annual number: 1 |
|
| PR1001 | Payment of annual fee |
Payment date: 19890503 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 19900501 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 19910513 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 19920803 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 19930531 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 19940801 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 19950728 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 19960724 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 19970312 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 19980727 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 19990805 Start annual number: 14 End annual number: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20000811 Start annual number: 15 End annual number: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20010808 Start annual number: 16 End annual number: 16 |
|
| PR1001 | Payment of annual fee |
Payment date: 20020806 Start annual number: 17 End annual number: 17 |
|
| PC1801 | Expiration of term |